8-K filing — Lipocine Inc. (LPCN)
Filed: 2026-10-20 AccNo: 0001493152-26-047693 Size: 17 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Lipocine Announces Initiation Of Phase 3 BLOOM Study Of Oral Brexanolone LPCN 1154 In Postpartum Depression, Planning About 120 Participants; First Dosing Expected Early Q4 2026
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nasdaq Falls Over 100 Points; US Crude Inventories Decline
U.S. stocks fell Wednesday, led by industrials. Crude inventories dropped unexpectedly, while Penguin Solutions and Lipocine surged; Caribou Biosciences
Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In Canada
Canada approves Lipocine’s TLANDO for adult males with testosterone deficiency. Partner Verity Pharma plans a launch by the end of 2026.
Dow Tumbles 350 Points; Constellation Brands Earnings Top Views
U.S. stocks fell Wednesday; Dow dropped 350 points. Energy rose, materials slid. Constellation beat estimates; oil gained while gold and silver fell.